Showing results (131-140 of 172) with videos related to

Sort By:
Pageof 18
Cancer Immunology Research|January 23, 2023
Tissue-Resident Memory T Cells in Pancreatic Ductal Adenocarcinoma Coexpress PD-1 and TIGIT and Functional Inhibition Is Reversible by Dual Antibody BlockadeHayden Pearce, Wayne Croft, Samantha M Nicol, et al.
The Journal of Infectious Diseases|April 11, 2022
Defective Monocyte Enzymatic Function and an Inhibitory Immune Phenotype in Human Immunodeficiency Virus-Exposed Uninfected African Infants in the Era of Antiretroviral TherapyLouise Afran, Kondwani C Jambo, Wilfred Nedi, et al.
British Journal of Haematology|May 28, 2021
DNA and modified vaccinia Ankara prime-boost vaccination generates strong CD8<sup>+</sup> T cell responses against minor histocompatibility antigen HA-1Suzy A Eldershaw, Hayden Pearce, Charlotte F Inman, et al.
Nature Communications|December 11, 2021
Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in EnglandGayatri Amirthalingam, Jamie Lopez Bernal, Nick J Andrews, et al.
Nature Immunology|May 30, 2017
Atypical chemokine receptor 1 on nucleated erythroid cells regulates hematopoiesisJohan Duchene, Igor Novitzky-Basso, Aude Thiriot, et al.
JCI Insight|May 18, 2018
Unique features and clinical importance of acute alloreactive immune responsesCharlotte F Inman, Suzy A Eldershaw, Joanne E Croudace, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|February 20, 2024
Interplay in galectin expression predicts patient outcomes in a spatially restricted manner in PDACOladimeji Abudu, Duy Nguyen, Isabel Millward, et al.
The Journal of Infection|September 3, 2023
Nasal mucosal IgA levels against SARS-CoV-2 and seasonal coronaviruses are low in children but boosted by reinfectionAlexander C Dowell, Gokhan Tut, Jusnara Begum, et al.
European Journal of Cancer (Oxford, England : 1990)|May 4, 2025
Phase II trial of atezolizumab (Anti-PD-L1) in the treatment of relapsed/refractory IIB/IVB mycosis fungoides/Sézary syndrome patients after previous systemic treatment. EORTC-1652-CLTG "PARCT"Rudolf Stadler, Gabriele Roccuzzo, Pablo Ortiz-Romero, et al.
Vaccine|November 19, 2019
A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adultsMorven Wilkie, Iman Satti, Alice Minhinnick, et al.
Pageof 18